A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2002
11/28/2002	US20020177621 Comprises aliphatic/aromatic alcohol and aliphatic/aromatic aldehyde; synergism; for use in room, closet or shoe box
11/28/2002	US20020177620 Prostanoic acid derivatives as agents for lowering intraocular pressure
11/28/2002	US20020177619 Steroid sulphatase inhibitors
11/28/2002	US20020177618 ERK (extracellular signal regulated kinase) inhibitors for treatment of cancer, inflammatory disorders, restenosis, and cardiovascular disease
11/28/2002	US20020177617 Method of treating migraines and pharmaceutical compositions
11/28/2002	US20020177616 Such as 2-(4-((((2R)-8-isopropoxy-chroman-2-yl)-methyl)amino) butyl)-1,2-benzisothiazol-3(2H)-one for prophylaxis and/or treatment of Parkinson's disease
11/28/2002	US20020177615 Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones
11/28/2002	US20020177614 Preventing neural tissue damage caused by adenosine-diphosphate- ribosylation of eucaryotic elongation factor-2 (EF-2)
11/28/2002	US20020177612 Rosiglitazone salts for glycaemic control useful for treatment of diabetes mellitus
11/28/2002	US20020177611 Pharmaceutical formulation comprising glycine as a stabilizer
11/28/2002	US20020177610 Hypolipidemics; treating obesity and disorders of lipid metabolism
11/28/2002	US20020177609 Fatty alcohol drug conjugates
11/28/2002	US20020177605 3-substituted isoquinolin-1-yl derivatives
11/28/2002	US20020177604 N-(4-chlorobenzyl)-6-(3-hydroxy-1-propynyl)-1-7-dimethyl-4-oxo-1,4 -dihydro(1,8)naphthyridine-3-carboxamide for example; inhibiting viral DNA polymerase; treating herpes virus infections
11/28/2002	US20020177603 5,10-dihydrobenzo(b)(1,8)naphthyridine compounds, N-oxides; 3,7-Dichloro-5-isopropoxymethyl-5-trifluoromethyl-5,10 -dihydrobenzo(b)(1,8)naphthyridine for example; combination therapy
11/28/2002	US20020177602 Antidiabetic formulation and method
11/28/2002	US20020177601 Inhibit the signal transduction by tyrosine kinases; e.g. 4-(3-chloro-4-fluorophenylamino)-6-(3-(4-(methoxycarbonyl-methyl)-1 -piperazinyl)propyloxy)-7-methoxyquinazoline; use such as antitumor agent
11/28/2002	US20020177600 Two or more ligand moieties covalently linked together by one or more linking groups enabling binding to multiple binding sites; increased efficacy, selectivity and duration; anti-proliferative and anticarcinogenic
11/28/2002	US20020177598 Inhibit activity of chemokines, macrophage inflammatory protein-1 (MIP-1 alpha) and RANTES; 1-((4-chlorophenoxy)methyl)-carbonyl-2-methyl-4-(4-fluorobenzyl)piperazine for example
11/28/2002	US20020177596 2,3,4,4a,5,6-hexahydro-1H-pyrazino(1,2-a)quinoxaline derivatives; treating depression, schizophrenia; (5-hydroxytryptamine=5HT) 5HT2a antagonist or a 5HT2c agonist
11/28/2002	US20020177593 Non-carbamate amine acetylcholinesterase inhibitor and a carrier; for example, 9-amino-1,2,3,4-tetrahydroacridine or 8-(3-(1-((3-fluorophenyl)methyl)-4-piperidinyl)-1-oxopropyl)-1,2,5,6 -tetrahydro-4H-pyrrolo(3,2,1-ij)quinolin-4-one
11/28/2002	US20020177591 Central nervous system (CNS); diazabicyclo compounds such as 1,4-Diaza-bicyclo(3.2.2)nonane-4-carboxylic acid, 4-cyclohexyl-phenyl ester; CNS-penetrant alpha 7 nicotinic receptor agonist
11/28/2002	US20020177590 Such as Alzheimer's disease, by administering olanzapine or salt thereof
11/28/2002	US20020177588 Selectivity
11/28/2002	US20020177587 Treating sexual dysfunction including erectile dysfunction, diabetes melitus, gastrointestinal disorders, including gastric paresis and cardiovascular disorders; cyclic guanosine 3',5'-monophosphate (cGMP)
11/28/2002	US20020177586 Method for treating fibrotic diseases or other indications ID
11/28/2002	US20020177585 Peroxidation reaction products of an alkene, such as geraniol; penetrating solvent, such as dimithyl sulfoxide; a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone.
11/28/2002	US20020177584 Single pot process for preparing metal picolinates from alpha pecoline
11/28/2002	US20020177583 A dithiocarbonyl compound; a metal cation; a modulator of cellular glutathione levels; and an inhibitor of the phosphorylation of choline.
11/28/2002	US20020177582 For diagnosing and treating urogenital disorders associated with atrophic vaginitis in symptomatic women having vaginal pH of 4.5 or above
11/28/2002	US20020177581 Novel anti-inflammatory androstane derivative
11/28/2002	US20020177580 Means and method for hormonal contraception
11/28/2002	US20020177579 Extended release formulation of water-soluble drugs
11/28/2002	US20020177578 3-hydroxy-4-methoxypyridine-2-carboxyamides N-substituted with a benzyl 9-member dilactone ring
11/28/2002	US20020177575 Identification of farnesyl-protein transferase as a target for systemic lupus erythematosus therapies
11/28/2002	US20020177563 Neutral glycolipid enhances protein C pathway anticoagulant activity.
11/28/2002	US20020177562 Dissolving in an acidified solvent and spray-drying to form a powder suitable for oral inhalation to the lung
11/28/2002	US20020177561 With an average degree of polymerisation of at least 15
11/28/2002	US20020177558 Method of treating, preventing or inhibiting central nervous system injuries and diseases
11/28/2002	US20020177556 Especially treating Alzheimer's disease with cetrorelix.
11/28/2002	US20020177553 Secreted and transmembrane polypeptides and nucleic acids encoding the same
11/28/2002	US20020177552 Colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions; alternatively, antigen presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a
11/28/2002	US20020177548 Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
11/28/2002	US20020177546 Treating with a mixture comprising insulin combined with serotonin.
11/28/2002	US20020177544 Adenoviral transfer vector for the gene transport of a dna sequence
11/28/2002	US20020177213 Tissue plasminogen activator-like protease
11/28/2002	US20020177209 Lipoprotein associated phospholipase A2, inhibitors thereof and use of the same in diagnosis and therapy
11/28/2002	US20020177145 Detection and classification of nervous system progenitor cells; obtain tissue, monitor expression of daedalos protein in sample, compare to control, ampified daedalos expression indicates presence of nervous system progenitor cells
11/28/2002	US20020176935 Microprecipitation method for preparing submicron suspensions
11/28/2002	US20020176912 Such as (6S)-tetrahydrofolic acid, and the 5-methyl, 5- or 10-formyl, 5,10-methylene, 5,10-methenyl, or 5-formimino derivatives; increasing folate intake such as to prevent birth defects
11/28/2002	US20020176911 Includes xanthan gum which improves tolerance (e.g. less gastrointestinal symptoms such as emesis, stool patterns and gas)
11/28/2002	US20020176904 Antiprotozal composition
11/28/2002	US20020176902 Synergistic proteoglycan compositions for treatment of inflammatory diseases
11/28/2002	US20020176900 Source of calcium, magnesium, selenium, manganese, zinc, and potassium, vitamin E, vitamin A, alpha-lipoic acid, extracts of Allium sativum, Medicago sativa, and Chondrus crispus, L-cysteine, L-glutamic acid, glycine, and glutathione
11/28/2002	US20020176898 Tea catechins in sustained release formulations as cancer specific proliferation inhibitors
11/28/2002	US20020176897 Treating cancer cells that express a membrane protein tNOX, a hormone-insensitive and drug-responsive form of NOX (NADH oxidase) specific to cancer cells
11/28/2002	US20020176894 For an azole antifungal or antibacterial drug; core and a drug emulsion layer containing the drug, an emulsifier, binder and absorbent aid such as citric acid; solubility, bioavailability
11/28/2002	US20020176892 Sterile gelled composition of a matrix containing an anionic "polymer" such as chondroitin sulfate blended with a nonionic polymer such as hydroxyethyl cellulose in given ratio; topically applying for pain relief from e.g. arthritis
11/28/2002	US20020176891 Topical gel delivery system
11/28/2002	US20020176889 And an excipient wherein the pH is within the range of 5.5-7.0; stability; dosage forms
11/28/2002	US20020176888 Oral dosage forms
11/28/2002	US20020176887 Methods of delivery of cetyl myristoleate
11/28/2002	US20020176886 Topical patch preparation containing a delayed-type hypersensitivity inducer and methods for using the same
11/28/2002	US20020176882 Additive the improvement and/or stabilization of the keeping quality of microbially perishable products
11/28/2002	US20020176876 A unique combination of antiinfammatory agent, bactericide, antioxidant, and an exfoliant as first phase, a circulatory enhancement agent, an antiinflammatory agent, a moisturizer as second phase for topical therapeutical skin treatment
11/28/2002	US20020176850 Immunotherapy of cancer with allogeneic lymphocytes
11/28/2002	US20020176849 Endomural therapy
11/28/2002	US20020176843 Polyamide particles as anti-irritant agents
11/28/2002	US20020176842 A dosage form comprising an ionizable active ingredient and an unloaded ion exchange resin, coated with a permeable membrane; drug release and absorption depending on the conditions under which the membrane dissolves
11/28/2002	US20020176827 Carrier and composition comprising polybutene with molecular weight of 300-3000 and one or more cosmetic or therapeutic actives, releasably associated to carrier
11/28/2002	US20020176825 Aerosols containing annealed particulate salbutamol and tetrafluoroethane
11/28/2002	US20020176824 Medicaments
11/28/2002	US20020176818 Radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid
11/28/2002	DE10141650C1 Safe transdermal therapeutic system for administration of fentanyl or analogous analgesics, having matrix layer of carboxy group-free polyacrylate adhesive providing high permeation rate
11/28/2002	DE10125763A1 New use of indirubin derivatives as VEGF inhibitors useful for preparing medicaments useful for e.g. treating cancer, autoimmune diseases, cardiovascular diseases or viral infections
11/28/2002	DE10125478A1 Treatment or prophylaxis of arterial thrombosis, using 5-quinolinesulfonylamino-benzimidazole derivatives having combined thrombin inhibiting and fibrinogen receptor inhibiting action
11/28/2002	DE10125145A1 New C-furanyl- or C-thienyl-methylamine derivatives, useful e.g. for treating arrhythmia, emesis, inflammation, cardiovascular or neurodegenerative disease, asthma, glaucoma or especially pain
11/28/2002	DE10124867A1 New substituted (hetero)aryl-alkenes or -alkynes, used as thrombin inhibitors, serine protease inhibitors, antithrombotic agents and intermediates
11/28/2002	DE10123958A1 Identifying ligands for G protein-coupled receptors, useful for treating cardiovascular disease, by using calcium-sensitive fluorophores in cells expressing G alpha proteins
11/28/2002	DE10123586A1 New 3,5-diamino-1,2,4-triazole derivatives, are cyclin dependent kinase inhibitors useful for treating e.g. cancer, autoimmune, cardiovascular or neurodegenerative diseases or viral infections
11/28/2002	CA2826505A1 Antiviral nucleosides
11/28/2002	CA2641760A1 Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
11/28/2002	CA2489768A1 Methods for preparation and use of psorospermin analogs
11/28/2002	CA2454551A1 Controlled release drug delivery device
11/28/2002	CA2450685A1 Compositions for the treatment of pigmentation disorders and methods for their manufacture
11/28/2002	CA2450535A1 Tri-and tetraaza-acenaphthylen derivatives as crf receptor antagonists
11/28/2002	CA2449442A1 Combination medicament for treatment of neoplastic diseases
11/28/2002	CA2448449A1 Treatment of renal fibrosis
11/28/2002	CA2448364A1 Composition and methods for affecting metallocorrinoid uptake
11/28/2002	CA2448280A1 Means and method for hormonal contraception
11/28/2002	CA2448271A1 Means and method for hormonal contraception
11/28/2002	CA2448270A1 Means and method for hormonal contraception
11/28/2002	CA2448197A1 Tricyclic dihydro-quinoline derivatives, method for preparing same and pharmaceutical compositions containing same
11/28/2002	CA2448191A1 Tricyclic dihydro-quinoline derivatives, method for preparing same and pharmaceutical compositions containing same
11/28/2002	CA2448174A1 Compounds capable of modulating the activity and stimulating the production of a catalytic antibody
11/28/2002	CA2448084A1 Aza hydroxylated ethyl amine compounds
11/28/2002	CA2448080A1 Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
11/28/2002	CA2448045A1 Identifying parasitic fungi of the organism, and treatment thereof
11/28/2002	CA2448031A1 Method for stabilising of nucleic acids
11/28/2002	CA2447942A1 A gene and uses therefor

1 ... 5637 5638 5639 5640 5641 5642 5643 5644 5645 5646 5647 5648 5649 5650 5651 5652 5653 5654 5655 5656 5657 ... 7860